Hayes Reports Payers Are Viewing in 2017

Posted by Silvana Schneider, Director Payer Services on May 11, 2017
Find me on:

popular_1200.jpgLast month, we gave you some insights into the most viewed reports in 2017 thus far. This week, we’d like to drill down a little further and show you three top reports that our payer clients, in specific, are reviewing from our Knowledge Center. In case you’re not a subscriber to our evidence solution, our Knowledge Center is a repository of unbiased health technology assessments (HTAs). From medical devices, to drugs, and genetic testing, you’ll find thoroughly scrutinized evaluations of the peer-reviewed, published research to give you the defensible information you need for your coverage policy determinations.

You can view a sample report by clicking the links below. If you’re not a member and you like what you see, you can contact us to purchase a full report.

Let’s take a look at the reports!

Coronary Artery Calcium Scoring for Risk Assessment and Stratification of Coronary Artery Disease in Asymptomatic Adults

cad_1200.jpgCoronary artery disease (CAD) is responsible for serious cardiac events, including myocardial infarction (MI), and is the leading cause of death in the United States. In patients without signs or symptoms, CAD may be heralded by atherosclerosis, the thickening and hardening of arteries due to plaque buildup, which results from the accumulation of fatty deposits and cell products, including calcium.

Coronary artery calcium (CAC) scoring can be viewed noninvasively with diagnostic imaging by using electron beam computed tomography (EBCT) or multidetector computed tomography (MDCT). To quantify CAC risk, an Agatston score is generated based upon a patient’s age, sex, and the sum of CAC measures for each of 16 defined segments of the coronary artery tree. Higher CAC scores indicate greater risk of CAD.

A large proportion of people are categorized in the “intermediate risk” category of global assessment instruments, for which treatment guidance is less clear than for low-risk or high-risk categories. Further, these instruments are not perfect. CAC, used in conjunction with global assessments, is intended to improve the accuracy of risk assessment and to reduce the number of patients classified as intermediate risk.

See a Sample of the Medical Technology Directory Report

View Sample Report

Hydrogen Breath Tests for Diagnosis of Small Intestinal Bacterial Overgrowth in Functional Bowel Disorders

hydrogen_1200.jpgFunctional bowel disorders (FBDs) are characterized by symptoms of pain, bloating, distention, and bowel changes that all occur in the absence of any apparent physiologic abnormalities. Irritable bowel syndrome (IBS) is a common FBD with estimated prevalence rates in the United States ranging from 11% to greater than 20%, and an estimated global prevalence of 11.2%. However, these estimates can vary considerably, depending on the diagnostic criteria used and the population studied.

Hydrogen Breath Tests involve ingesting a carbohydrate substrate, obtaining breath samples prior to and at timed intervals after ingesting the substrate, and analyzing the samples for H2 content. Intestinal bacteria ferment the carbohydrate substrate and produce hydrogen gas (H2), which diffuses into the bloodstream and is excreted in exhaled breath.

See a Sample of the Medical Technology Directory Report

View Sample Report

LifeVest System (Asahi Kasei Corp.) Wearable Cardiac Defibrillator for Prevention of Sudden Cardiac Arrest

defib_1200.jpgThe LifeVest is a wearable cardioverter defibrillator (WCD) used on an outpatient basis. The noninvasive LifeVest is worn on the outside of the body and is designed to perform the same functions as an implantable cardioverter defibrillator (ICD). The programmable LifeVest incorporates an algorithm to manage disturbances in the electrocardiogram (ECG) signal, while allowing for responses by conscious patients to alarms to prevent inappropriate shocks. The LifeVest is a combination of 2 different devices. As a cardioverter, it uses low-energy electrical shocks to restore a normal rhythm in a heart undergoing ventricular tachycardia. As a defibrillator, it uses high-energy shocks to return a heart in a state of ventricular fibrillation to a normal rhythm. The device is intended for temporary use in adult patients who are at high risk for sudden cardiac arrest (SCA) and sudden cardiac death (SCD), but who are not immediate candidates for an ICD. The device also records up to 75 minutes of ECG data allowing physician playback of any arrhythmic events through the secure website.

See the Sample Search and Summary

View Sample Report